St.

Mary’s College
Bachelor of Science in Nursing
DRUG STUDY
Name of Patient: Attending Physician: Dr.
Chief Complaint: Submitted to:
Diagnosis:
Date Generi Brand Classification Indication Mechanis Dosage & Time Adverse Nursing Student’s CI’
c Name m of Action Frequenc Given Reaction Consideration Sign Sign
Name y
Citalopr Celexa Antidepressa Citalopram The mech Celexa Dry mouth Communicati
am nt is not anism of (citalopra (20%) ng
indicated action of c m) should Nausea information
for any italopram  be (21%) about
condition HBr as an administer Somnolence relevant QTc
in pediatric antidepres ed at an (18%) prolongation
patients sant is initial Insomnia monitoring
less than presumed dose of 20 (15%) and
18 years of to be mg once Xerostomia documentatio
age. In a linked to daily, with (20%) n to
pooled potentiatio an Increased prescribers.
analysis of n of increase sweating
placebo- serotonergi to a (11%)
controlled c activity in maximum
1-10% Giving
trials of the central dose of 40
antidepres nervous mg/day at opinion on
Tremor (8%)
sants (n = system an interval whether or
Diarrhea
4,500 resulting of no less not there is
(8%)
pediatrics from its than one any likely risk
Ejaculation
and inhibition of week. for
disorder (6%)
escitalopram,
77,000 CNS Doses Rhinitis (5%) the active S-
adults), neuronal above 40 Upper isomer of
there was reuptake of mg/day respiratory citalopram (ie,
an serotonin are not infection should we
increased (5-HT). recomme (5%) just switch all
risk for nded due Dyspepsia these patients
suicidal to the risk (5%) to
thoughts of QT escitalopram
and prolongati since there is
behaviors on. no current
in patients Additionall warning on
24 years of y, the only this drug?).
age and study
younger pertinent
receiving to dose
an response Discussing
antidepres for and
sant effectiven documenting
versus ess did the risk of
placebo, not undertreating
with demonstr the various
considerab ate an disorders for
le variation advantage which
in the risk for the 60 citalopram is
of mg/day prescribed
suicidality dose over and the risks
among the 40 and benefits
drugs. mg/day of alternative
dose. therapies.

Outlining
factors to
consider and
document
regarding use
of citalopram
and
escitalopram
in patients
also using
PPIs or oral
contraceptive
s because
these clinical
situations
have
generated the
bulk of the
questions
from
prescribers
due to the
potential for
pharmacokine
tic drug
interaction
ordering
alerts.